Our observation that that high IGFBP7 expression was associated with worse clinical outcome in SCAN-B, a large contemporary population-based breast cancer cohort unexposed to ganitumab, supports the concept that high IGFBP7 expression reveals more than increased resistance to ganitumab. This evidence concerns the gene IGFBP7 and breast cancer.